Craig-Hallum Downgrades Radnet to Hold

By Jason Carr

Radnet (NASDAQ: RDNT) received a Hold rating from Craig-Hallum analyst William Bonello today. The company’s shares opened today at $5.67.

According to, Bonello is a 2-star analyst with an average return of 1.0% and a 42.9% success rate. Bonello covers the Healthcare sector, focusing on stocks such as Meridian Bioscience Inc., Quest Diagnostics Inc., and Trinity Biotech Plc.

Radnet has an analyst consensus of Hold.

The company has a one year high of $7.98 and a one year low of $4.66. Currently, Radnet has an average volume of 118.1K.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. Most recently, in September 2016, Stephen Forthuber, the EVP of RDNT sold 20,000 shares for a total of $143,600.

RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The company offers magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy and other related procedures. RadNet was founded by Howard Berger in 1980 and is headquartered in Los Angeles, CA.